Outcomes by measure
- " Area under the curve" how much lower the CIWA-Ar scores are for the cases, compared to the controls (until the primary endpoint is reached). This endpoint will utilize the average CIWA-Ar scores in each of the nine 8 hour periods of the 72 hours study.
- " Per protocol" eradication rate
- "% of seroconverters (anti-rota IgA post dose 2), RV-IgA concentration, presence of rotavirus in stool samples. Occurrence of solicited symptoms, any grade 2 or 3 fever, vomiting or diarrhea, unsolicited adverse events and serious adverse events .
- "-Clinical Benefit Rate during treatment
- "almost clear") during CP 690,550 re treatment (Period C).
- "Anthracycline-induced cardiotoxicity" and clinical cardiac outcomes
- "anti-HBs, anti-diphtheria, anti-tetanus, anti-BPT & anti-PRP conc. & GMCs; vaccine response to BPT
- "Average Pain Over the Last 24 Hours" Score of the Study Knee at Week 12 of the Double Blind Phase.
- "Average Pain Over the Last 24 Hours" Scores at Weeks 4, 8, and 12 of the Double-blind Phase.
- "Beads in the Jar" Task
- "Before Pneumo 23 administration: Antibody concentrations (ELISA) to pneumococcal serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F & seropositivity (S+) status* (>= 0.05 µg/mL) * also measured 10-15 days after dose of Pneumo 23
- "Body-Mass index, Airflow Obstruction, Dyspnea, Exercise Capacity" Index (BODE index)
- "Change from Baseline in BMI"
- "Change from Baseline in HbA1c"
- "Change from Baseline in Systolic Blood Pressure"
- "Clear - almost clear" Physician Global Assessment (PGA) at Week 6 visit.
- "Concomitant and Vegetative Symptoms Score" (CVSS) rated by patients using VAS
- "Consensus Auditory-Perceptual Evaluation of Voice" (CAPE-V)
- "craving" measured using the Marijuana craving questionaire and the tobacco craving questionaire
- "death" of the kidney (initiation of renal replacement therapy)
